Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
Sarah Frey, Teresa Po‐Yu Chiang, Caoilfhionn M Connolly, Mayan Teles, Jennifer L. Alejo, Brian J. Boyarsky, Lisa Christopher‐Stine, William A. Werbel, Allan B. Massie, Dorry L. Segev, Julie J. Paik
Topics & Concepts
MedicineAntibodyDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCoronavirus disease 2019 (COVID-19)VirologyMessenger RNAInternal medicineBiologyInfectious disease (medical specialty)GeneGeneticsSARS-CoV-2 and COVID-19 ResearchViral Infections and Immunology ResearchImmunotherapy and Immune Responses